#USA #New York #Levi & Korsinsky #Regeneron Pharmaceuticals #Eylea

Regeneron Pharmaceuticals Faces Class Action Lawsuit

Overview

On February 25, 2025, Levi & Korsinsky, LLP, a law firm specializing in investor protection, informed shareholders of Regeneron Pharmaceuticals, Inc. about a significant class action lawsuit targeting the company. The case, lodged on behalf of investors adversely affected by alleged securities fraud, spans the period between November 2, 2023, and October 30, 2024. Investors who suffered losses during this timeframe should be aware of the deadline to act: March 10, 2025.

Allegations

The core of the lawsuit claims that Regeneron made misleading statements regarding its financial practices and the pricing strategy for its anti-VEGF product, Eylea. Specific allegations include:
1. Payment Practices: Regeneron allegedly paid credit card processing fees to distributors with stipulations that these distributors would not pass on the increased costs to customers. This created an illusion of lower prices for Eylea, misinforming the market about its true sales figures.
2. Market Manipulation: The payments made by Regeneron allowed them to advertise boosted sales for Eylea, which may have created an unfair competitive advantage, especially among retina practices sensitive to pricing.
3. Reporting Discrepancies: The lawsuit argues that Regeneron failed to accurately report the payment of credit card fees as price reductions, which led to the company overstating the average selling price (ASP) to federal agencies. This contravention of the False Claims Act is particularly serious as it undermines the integrity of pricing reported in the healthcare sector.

Implications for Investors

For current or former shareholders of Regeneron, this class action lawsuit may present a crucial opportunity for recourse. If you experienced financial losses related to your holdings during the period in question, you can join the lawsuit without any upfront costs. Participating in this class action could entitle you to compensation, should the case succeed.

While it is voluntary to assume the role of lead plaintiff, it is important to act swiftly as the deadline approaches. Interested parties should contact Joseph E. Levi, Esq. via email at info@zlk.com or by phone at (212) 363-7500 for further details and assistance in filing claims.

Why Levi & Korsinsky?

With over two decades of experience in securities litigation, Levi & Korsinsky has established a formidable reputation. The firm has recovered hundreds of millions for shareholders and regularly ranks among the top securities litigation firms in the U.S. This experience positions them well to advocate for investors in complex legal environments.

Conclusion

As the implications of this lawsuit unfold, Regeneron investors are advised to stay alert and informed about developments. With a strong legal team at their back, elaborating on the case could lead to significant repercussions for the company, reshaping investor dynamics for years to come. Keep an eye on the March 10th deadline, as the opportunity to seek justice and recovery is fast approaching.